TMO Stock Analysis

Key Financial Metrics

📊Valuation

P/E Ratio
17.58
Forward P/E
15.07
P/S Ratio
1.21
P/B Ratio
5.02
EV/EBITDA
12.74
EV/Revenue
1.30
PEG Ratio
1.40

💰Profitability

Gross Margin
34.2%
Operating Margin
23.3%
Net Margin
17.4%
ROE
23.5%
ROA
8.1%
ROIC
15.1%

📈Growth

Revenue Growth (YoY)
5.4%
EPS Growth (YoY)
7.8%
FCF Growth
10.4%

🏦Financial Health

Debt/Equity
0.73
Current Ratio
1.33
Quick Ratio
1.07
Interest Coverage
11.72

💵Dividends

Dividend Yield
1.4%
Payout Ratio
28.1%
Dividend Growth
5.0%

📋Per Share

EPS
$24.72
Book Value/Share
$85.69
FCF/Share
$19.84
Revenue/Share
$89.00

Proprietary Model

Finlytics Score

Instant view of the current conviction score for TMO, with component-level transparency.

Refreshing score...Loading live inputs

Pro Feature

Peer Comparison

Compare valuation, growth, margins, and Finlytics Score against the closest sector names.

Previewing 2 peers

🔒 See full peer comparison with Pro — $29/month

Upgrade to Pro

Company overview

About Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Finlytics combines this business profile with an interactive DCF valuation, bear/base/bull intrinsic value scenarios, financial statements, peer comparison, and the Finlytics Score so investors can evaluate TMO stock from multiple angles.

Finlytics Score
63/100
Trailing P/E
33.4
Revenue Growth
+10.5%
Market Cap
$230.0B

Price History

1Y Performance: +3.10%

Financial Statements

Reported fundamentals across filing periods

Revenue, margins, and earnings power across reported periods.

Positive changeNegative change

Annual filings

Loading statement history